Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status

Critical Reviews in Oncology/Hematology

Volumn 66, Issue 1, 2008, Pages 84-90

  Abbrederis, K ^a   Lorenzen, S ^a   von Weikersthal, L Fischer ^b   Vehling Kaiser, U ^c   Schuster, T ^d   Rothling, N ^a   Peschel, C ^a   Lordick, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM ST MARIEN   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Docetaxel; Elderly patients; Gastric cancer; Performance status

Indexed keywords

DEXAMETHASONE; DOCETAXEL; FLUOROURACIL;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; DEATH; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS;

EID: 40049109856     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.12.001     Document Type: Review

References (25)

1. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8 (1997) 163-168
2. Pyrhonen S., Kuitunen T., Nyandoto P., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
3. Murad A., Santiago F., Petroianu A.A., et al. Modified therapy with 5-fluouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
4. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006) 2903-2909
5. Einzig A.I., Neuberg D., Remick S.C., et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13 (1996) 87-93
6. Mai M., Sakata Y., Kanamaru M., et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho 26 (1999) 487-496 [In Japanese]
7. Mavroudis D., Kourousis C., Androulakis N., et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Oncol 23 (2000) 341-344
8. Sulkes A., Smyth J., Sessa C., et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70 (1994) 380-383
9. Wilke H., Vanhoefer U., Harstrick A., et al. Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 17 (1998) 305 [Abstract]
10. Taguchi T., Sakata Y., Kanamaru R., et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group Trial. Gan To Kagaku Ryoho 25 (1998) 1915-1924 [In Japanese]
11. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1289-1383
12. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 (2004) 2720-2726
13. http://ec.europa.eu/health/ph_information/reporting/state_health_reporting_en.htm.
14. Hainsworth J.D., Burris III H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16 (1998) 2164-2168
15. Lilenbaum R.C., Schwartz M.A., Seigel L., et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer 92 (2001) 2158-2163
16. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
17. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
18. Charlson M.A.P.P., Ales K., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40 5 (1987) 373-383
19. Wilson D., Hiller L., and Geh L.L. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 17 (2005) 81-90
20. Graziano F., Catalano V., Baldelli A.M., et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11 (2000) 1263-1266
21. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32 (2002) 248-254
22. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24 (2006) 4991-4997
23. Chau I., Norman A.R., Cunningham D., et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22 (2004) 2395-2403
24. Lewis J., Kilgore M., Goldman D., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
25. Ilson D.H., Forastiere A., Arquette M., et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6 (2000) 316-323